What is Rain Oncology Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rain Oncology's interest expense for the
three
months ended in Sep. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rain Oncology's Operating Income for the
three
months ended in Sep. 2023 was $ -8.08 Mil. Rain Oncology's Interest Expense for the
three
months ended in Sep. 2023 was $ 0.00 Mil.
Rain Oncology has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Rain Oncology Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rain Oncology (NAS:RAIN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Rain Oncology's Interest Expense for the
three
months ended in Sep. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Sep. 2023 was $-8.08 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2023 was $0.00 Mil.
Rain Oncology's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
| Rain Oncology had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Rain Oncology Inc has enough cash to cover all of its debt. Its financial situation is stable.
Rain Oncology (Rain Oncology) Business Description
Traded in Other Exchanges
N/A
Address
8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Executives
| Kevin C Tang |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Josephine Bruce |
officer: Principal Fin. & Acc. Officer |
8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560 |
| Tang Capital Partners Lp |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Tang Capital Management Llc |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Boxer Capital, Llc |
other: See remarks. |
12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
| Boxer Asset Management Inc. |
other: See remarks |
CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
| Joseph Lewis |
other: See remarks. |
PO BOX N7776, LYFORD BAHAMAS |
| Aaron I. Davis |
director |
12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
| Erik Atkisson |
officer: General Counsel and CCO |
C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306 |
| Franklin M Berger |
director |
1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
| Biotechnology Value Fund L P |
other: See Explanation of Responses |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Avanish Vellanki |
director, officer: President and CEO |
8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Cormorant Asset Management, Lp |
10 percent owner |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Gorjan Hrustanovic |
director |
C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Rain Oncology (Rain Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAIN has been successfully added to your 